ALPHATEC HOLDINGS INC. Logo
US02081G2012
A2AP5V
ATEC

ALPHATEC HOLDINGS INC.

Loading quotes...

Forecast

The analysts' average price target is €11.85 (+83.15%). The median is €11.39 (+76.04%).

Buy
  17
Hold
  3
Sell
  1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Alphatec Holdings: CEO makes $1 million insider purchase, revenue and EBITDA significantly increased

    Alphatec Holdings reports Q2 revenue rose 15% to $213.5 million and EBITDA grew 53% to $36 million, driven by 20% more cases performed by surgeons. The company highlights its complete solution for more precise and faster spinal surgeries. Full-year revenue is expected to be $882 million. The CEO personally invested $1 million, putting short positions under pressure. » More on finanzen.net


  • Alphatec Holdings: CEO purchase triggers short squeeze and stock rises about 20%

    CEO Patrick Miles bought $1.01 million of his own shares near the 52-week low. High short interest led to covering, causing the stock to rise by nearly 20% on September 11, 2026 on increased volume. The company reports 15% revenue growth and positive free cash flow. » More on finanzen.net


  • Alphatec Holdings: CEO buy near 52-week low sends stock sharply higher

    Alphatec Holdings' stock rose about 19% in afternoon trading after CEO Patrick Miles purchased 115,000 shares worth roughly $1.01 million at a weighted average price of $8.81. The purchase was made near the 52-week low and is seen as a strong insider vote of confidence, which, together with high short interest, contributed to a short squeeze. The company also recently reported a 15% revenue increase to $213.5 million, positive free cash flow, and reaffirmed its full-year guidance of around $882 million, while US markets overall showed a recovery. » More on de.investing.com


  • Alphatec confirms growth model and full-year targets at Wells Fargo conference

    Alphatec said procedure volume was about 20% higher in the first half and reaffirmed its 2026 forecast of $882 million revenue, $140 million EBITDA and $20 million free cash flow. Management cited increasing surgeon adoption, EOS robotics, software and the Theradaptive acquisition as the main growth drivers, but acknowledged near-term pressure from lower revenue per procedure and reduced follow-up rates for biologics. For 2027 the company is targeting $1 billion in revenue, roughly 18% EBITDA margin and $65 million free cash flow, and sees further upside from margin improvements. Alphatec expects rising surgeon acceptance and product penetration to support long-term growth of 15–20% annually. » More on de.investing.com


  • Alphatec posts Q1 revenue and surgical volume gains, secures cheaper debt and issues 2026 guidance

    Alphatec reported Q1 2026 total revenue of $192 million, with surgical revenue up 17% and surgical case volume rising 21%; non-GAAP adjusted EBITDA reached $21 million and trailing twelve-month free cash flow was $7 million. The company secured a new bank facility that cuts annual interest expense by over $6 million and extends debt maturities to 2031, ending the quarter with $140 million in cash. For full-year 2026 Alphatec guides total revenue of about $882 million (≈15% growth), surgical revenue near $805 million, adjusted EBITDA around $134 million (15% of revenue) and at least $20 million in free cash flow. » More on finance.yahoo.com

Financials

In the last quarter, ALPHATEC HOLDINGS INC. had revenue of €195.26m and net profit of -€4.83m
(EUR) September 2026
YoY
Revenue 195.26m 16.61%
Gross profit 139.71m 19.41%
Net profit -4.83m 80.17%
EBITDA 20.85m 414.89%

Fundamentals

Metric Value
Market capitalization
€981.19m
Number of shares
155.14m
52-week high/low
€21.22 - €6.11
Dividends No
Beta
0.78
P/E ratio
-12.39
PEG ratio
-0.18
P/B ratio
51.27
P/S ratio
1.28

Company profile

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.

Name
ALPHATEC HOLDINGS INC.
CEO
Patrick S. Miles
Headquarters Carlsbad, ca
USA
Website
Sector
Consumer Discretionary
Industry
Household Durables
IPO
12/06/2006
Employees 913

Ticker symbols

Exchange Symbol
NASDAQ
ATEC
Frankfurt
L1Z1.F
Düsseldorf
L1Z1.DU
München
L1Z1.MU
🍪

Parqet  uses cookies. Learn more